ProtAffin is a clinical stage European biotechnology company developing a novel class of next generation biopharmaceuticals applicable to high-priority disease targets in the fields of inflammation, respiratory disease and oncology. The company’s CellJammer® discovery technology is used to discover and develop novel biopharmaceuticals by engineering decoy mutants of chemokines and growth factors.

ProtAffin is located in Graz, Austria and in London, UK.